AJMC Staff


What We're Reading: Ineffective COVID-19 Drugs; Panel Advises Fourth Dose in Israel; Physician Mental Health Amid Pandemic

January 25, 2022

FDA significantly restricts the use of 2 COVID-19 monoclonal antibody treatments ineffective against the Omicron variant; an expert panel advises the Israeli government to offer a fourth COVID-19 vaccine dose to adults; there was a substantial increase in visits for mental health and substance abuse among physicians with no prior history during the pandemic.

Hurvitz: CDK4/6 Inhibitors With Endocrine Therapy Is the “Gold Standard” in the First Line for HR+/HER2-Negative Advanced Breast Cancer

January 24, 2022

Sara A. Hurvitz, MD, of UCLA Health spoke with The American Journal of Managed Care® (AJMC®) about advanced hormone receptor–positive (HR+), HER2-negative breast cancer and the emergence of CDK4/6 inhibitors with endocrine therapy as the “gold standard” for first-line treatment.

What We're Reading: Fully Vaccinated Designation; COVID-19 Infection, Infertility in Men; Faster, Cheaper Clinical Trials

January 24, 2022

The CDC is working to change its definition of being fully vaccinated against COVID-19; a study finds that men who tested positive for COVID-19 showed a short-term decline in fertility; a nonprofit group of scientists seeks to optimize the clinical trial process and reduce cost.

What We’re Reading: Unvaccinated Seniors at Higher Risk for Hospitalization, Nursing Homes in Crisis; Alzheimer Groups Protest

January 21, 2022

Unvaccinated older adults are 49 times more likely to be hospitalized after contracting COVID-19; nursing homes are experiencing a major staffing crisis; major Alzheimer groups plan to meet with federal officials and lawmakers to protest the CMS drug proposal.

What We’re Reading: Free N95 Masks, COVID-19 Rapid Tests; Easing Limits on Blood Donors; Counterfeit HIV Drugs

January 19, 2022

The Biden administration will distribute 400 million nonsurgical N95 masks; a study aims to develop a questionnaire to enable gay and bisexual men to donate blood; counterfeit versions of Gilead HIV treatments were discovered in 9 states.

CYNK-101 Receives Fast Track Designation for HER2-Positive Gastric/GEJ Cancers

January 18, 2022

Natural killer cell therapy CYNK-101 was granted fast track designation by the FDA to treat HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with standard chemotherapy, trastuzumab, and pembrolizumab.